Organoids, and by extension tumor organoids, are the only in vitro technology to faithfully recapitulate original tissue physiology, providing a fast and cost-effective model for applications such as in vitro drug screens. Organoids are easily scalable, like 2D cell lines, and they are highly clinically relevant with high predictivity for patient drug response. These beneficial features enable researchers to make better decisions earlier in drug discovery and provide increased confidence that selected drug candidates will have better translatability. Compared to other advanced culture systems, 3D in vitro organoids are more robust and show enhanced reproducibility because they are very stable genetically and phenotypically. Furthermore, they have consistent growth kinetics and performance across several passages, with scalable material available for repeat studies. These characteristics lead to reproducible, higher quality data, which is key to selecting successful drug candidates. This talk will summarize a study that highlights the measuring potential of synergistic effects of combination therapy using matrix screens.
- Learn how organoids can impact drug development decisions for targeted agents and immune-therapeutics with higher throughput and novel high-content image analysis
- Understand how to assess potential synergistic interactions using a matrix screen across multiple organoid models
- Make confident decisions on combination strategies before progressing drug candidates